These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 26147657)

  • 1. Role of isocitrate dehydrogenase 1/2 (IDH 1/2) gene mutations in human tumors.
    Liu X; Ling ZQ
    Histol Histopathol; 2015 Oct; 30(10):1155-60. PubMed ID: 26147657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer.
    Clark O; Yen K; Mellinghoff IK
    Clin Cancer Res; 2016 Apr; 22(8):1837-42. PubMed ID: 26819452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDH mutations in cancer and progress toward development of targeted therapeutics.
    Dang L; Yen K; Attar EC
    Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
    Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
    J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.
    Yang H; Ye D; Guan KL; Xiong Y
    Clin Cancer Res; 2012 Oct; 18(20):5562-71. PubMed ID: 23071358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting isocitrate dehydrogenase (IDH) in cancer.
    Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
    Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis.
    Ohba S; Hirose Y
    Neurol Med Chir (Tokyo); 2016; 56(4):170-9. PubMed ID: 26960449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological Role and Therapeutic Potential of IDH Mutations in Cancer.
    Waitkus MS; Diplas BH; Yan H
    Cancer Cell; 2018 Aug; 34(2):186-195. PubMed ID: 29805076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
    Gross S; Cairns RA; Minden MD; Driggers EM; Bittinger MA; Jang HG; Sasaki M; Jin S; Schenkein DP; Su SM; Dang L; Fantin VR; Mak TW
    J Exp Med; 2010 Feb; 207(2):339-44. PubMed ID: 20142433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IDH mutations in tumorigenesis and their potential role as novel therapeutic targets.
    Krell D; Mulholland P; Frampton AE; Krell J; Stebbing J; Bardella C
    Future Oncol; 2013 Dec; 9(12):1923-35. PubMed ID: 24295421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isocitrate dehydrogenase gene mutations and 2-hydroxyglutarate accumulation in esophageal squamous cell carcinoma.
    Miyake K; Baba Y; Ishimoto T; Hiyoshi Y; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Ogata Y; Nagayama M; Silsirivanit A; Kobayashi D; Araki N; Baba H
    Med Oncol; 2018 Nov; 36(1):11. PubMed ID: 30506321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma.
    Mohammad N; Wong D; Lum A; Lin J; Ho J; Lee CH; Yip S
    Histopathology; 2020 Apr; 76(5):722-730. PubMed ID: 31609487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
    Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H
    PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
    Han CH; Batchelor TT
    Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic dysregulation in cancers by isocitrate dehydrogenase 2 (IDH2).
    Nayarisseri A; Bandaru S; Khan A; Sharma K; Bhrdwaj A; Kaur M; Ghosh D; Chopra I; Panicker A; Kumar A; Saravanan P; Belapurkar P; Mendonça Junior FJB; Singh SK
    Adv Protein Chem Struct Biol; 2024; 141():223-253. PubMed ID: 38960475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.
    Sharma H
    Curr Top Med Chem; 2018; 18(6):505-524. PubMed ID: 29773061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
    Kato Kaneko M; Ogasawara S; Kato Y
    Tohoku J Exp Med; 2013 Jun; 230(2):103-9. PubMed ID: 23782684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.
    Ward PS; Lu C; Cross JR; Abdel-Wahab O; Levine RL; Schwartz GK; Thompson CB
    J Biol Chem; 2013 Feb; 288(6):3804-15. PubMed ID: 23264629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.
    Ma R; Yun CH
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2912-2917. PubMed ID: 30131249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2.
    Borodovsky A; Seltzer MJ; Riggins GJ
    Curr Opin Oncol; 2012 Jan; 24(1):83-9. PubMed ID: 22080945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.